This effect is confirmed, ex vivo, in human specimens from glioma patients and, in vivo, in a mouse model of glioma, where TRAM-34 treatment induced an increase of pro-inflammatory and a reduction of anti-inflammatory gene expression in infiltrating CD11b+ cells. Here, ITGAM is linked to glioma.